Is there a role for hemopoietic stem-cell transplantation in CTCL?
The role of autologous and allogeneic stem-cell transplantation (SCT) in the treatment of cutaneous T-cell lymphoma (CTCL) is reviewed. Patients most likely to benefit are those with advanced-stage disease, multiple relapses, and short remissions; chemosensitive disease is also a prerequisite for these treatments. Autologous SCT produces high response rates in patients with peripheral T-cell lymphoma, but these are generally of short duration. This therapy is relatively safe to administer, with little transplant-related mortality. In contrast, allogeneic SCT may be highly toxic and result in transplant-related mortality, but it has the potential to produce long-lasting responses. Prospective studies of these treatments in patients with CTCL are required. Nevertheless, selected patients could be considered for allogeneic SCT, preferably early in their disease when their performance status is still good.
Dearden
Claire
C
The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. claire.dearden@rmh.nhs.uk
D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000601:surgery*; D016411:Lymphoma, T-Cell, Peripheral / Q000276:immunology / Q000601:surgery*; D012878:Skin Neoplasms / Q000276:immunology / Q000601:surgery*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous